Benedikt Pelletier1, Sotirios Spiliopoulos2, Thomas Finocchiaro3, Felix Graef3, Kristin Kuipers3, Marco Laumen3, Dilek Guersoy2, Ulrich Steinseifer3, Reiner Koerfer2, Gero Tenderich2. 1. Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH-Aachen University, Aachen, Germany pelletier@hia.rwth-aachen.de. 2. Department for the Surgical Therapy of end-stage Heart Failure and Mechanical Circulatory Support, Heart- and Vascular Center Duisburg, Duisburg, Germany. 3. Department of Cardiovascular Engineering, Institute of Applied Medical Engineering, Helmholtz Institute, RWTH-Aachen University, Aachen, Germany.
Abstract
OBJECTIVES: Owing to the lack of suitable allografts, the demand for long-term mechanical circulatory support in patients with biventricular end-stage heart failure is rising. Currently available Total Artificial Heart (TAH) systems consist of pump units with only limited durability, percutaneous tubes and bulky external equipment that limit the quality of life. Therefore we are focusing on the development of a fully implantable, highly durable destination therapy total artificial heart. METHODS: The ReinHeart-TAH system consists of a passively filling pump unit driven by a low-wear linear drive between two artificial ventricles, an implantable control unit and a compliance chamber. The TAH is powered by a transcutaneous energy transmission system. The flow distribution inside the ventricles was analysed by fluid structure interaction simulation and particle image velocimetry measurements. Along with durability tests, the hydrodynamic performance and flow balance capability were evaluated in a mock circulation loop. Animal trials are ongoing. RESULTS: Based on fluid structure interaction simulation and particle image velocimetry, blood stagnation areas have been significantly reduced. In the mock circulation loop the ReinHeart-TAH generated a cardiac output of 5 l/min at an operating frequency of 120 bpm and an aortic pressure of 120/80 mmHg. The highly effective preload sensitivity of the passively filling ventricles allowed the sensorless integration of the Frank Starling mechanism. The ReinHeart-TAH effectively replaced the native heart's function in animals for up to 2 days. CONCLUSIONS: In vitro and in vivo testing showed a safe and effective function of the ReinHeart-TAH system. This has the potential to become an alternative to transplantation. However, before a first-in-man implant, chronic animal trials still have to be completed.
OBJECTIVES: Owing to the lack of suitable allografts, the demand for long-term mechanical circulatory support in patients with biventricular end-stage heart failure is rising. Currently available Total Artificial Heart (TAH) systems consist of pump units with only limited durability, percutaneous tubes and bulky external equipment that limit the quality of life. Therefore we are focusing on the development of a fully implantable, highly durable destination therapy total artificial heart. METHODS: The ReinHeart-TAH system consists of a passively filling pump unit driven by a low-wear linear drive between two artificial ventricles, an implantable control unit and a compliance chamber. The TAH is powered by a transcutaneous energy transmission system. The flow distribution inside the ventricles was analysed by fluid structure interaction simulation and particle image velocimetry measurements. Along with durability tests, the hydrodynamic performance and flow balance capability were evaluated in a mock circulation loop. Animal trials are ongoing. RESULTS: Based on fluid structure interaction simulation and particle image velocimetry, blood stagnation areas have been significantly reduced. In the mock circulation loop the ReinHeart-TAH generated a cardiac output of 5 l/min at an operating frequency of 120 bpm and an aortic pressure of 120/80 mmHg. The highly effective preload sensitivity of the passively filling ventricles allowed the sensorless integration of the Frank Starling mechanism. The ReinHeart-TAH effectively replaced the native heart's function in animals for up to 2 days. CONCLUSIONS: In vitro and in vivo testing showed a safe and effective function of the ReinHeart-TAH system. This has the potential to become an alternative to transplantation. However, before a first-in-man implant, chronic animal trials still have to be completed.
Authors: Muath Bishawi; Jun-Neng Roan; Jordan Richards; Zachary Brown; Laura Blue; Mani A Daneshmand; Jacob N Schroder; Dawn E Bowles; Carmelo A Milano Journal: J Vis Exp Date: 2018-05-11 Impact factor: 1.355
Authors: Annemijn Vis; Maziar Arfaee; Husain Khambati; Mark S Slaughter; Jan F Gummert; Johannes T B Overvelde; Jolanda Kluin Journal: Nat Rev Cardiol Date: 2022-06-06 Impact factor: 32.419
Authors: Kristin Unthan; Felix Gräf; Marco Laumen; Thomas Finocchiaro; Christoph Sommer; Hermann Lanmüller; Ulrich Steinseifer Journal: Biomed Res Int Date: 2015-10-25 Impact factor: 3.411